Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57245 | 0.90 | KMT2A (0.50) | KMT2AATMCES2CES1MEN1 | |
| SCHEMBL28555175 | 0.82 | KMT2A (0.52) | KMT2AMEN1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL14424402 | 0.82 | ALOX15 (0.50) | KMT2AATMMEN1ALDH1A1FAAH | |
| SCHEMBL3946410 | 0.82 | ALDH1A1 (0.49) | KMT2AATMMEN1ALDH1A1FAAH | |
| SCHEMBL10709297 | 0.80 | NFE2L2 (0.53) | KMT2ACES2CES1MEN1ALDH1A1 | |
| Guanidine SCHEMBL27421363 | 0.80 | KMT2A (0.45) | KMT2AATMCES2CES1MEN1 | |
| SCHEMBL13246362 | 0.80 | LMNA (0.57) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL18671115 | 0.80 | KMT2A (0.44) | KMT2AATMCES2CES1MEN1 | |
| SCHEMBL10710114 | 0.79 | KMT2A (0.46) | KMT2AATMCES2CES1MEN1 | |
| SCHEMBL14389790 | 0.78 | KMT2A (0.46) | KMT2AATMCES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | KMT2A 2377/4885ATM 2218/4885CES2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.